The effect of GLP-1RA on the eGFR-related endpoint worsening kidney function was neutral in the main analysis (HR 0.86, 95% CI 0.721.02), while a statistically significant benefit was detected in the sensitivity analysis excluding ELIXA (HR 0.82, 95% CI 0.690.98) [11]
Williams recommends a conversation between an eye doctor, primary care doctor, and, if pertinent, a neurologist or other subspecialist, to decide how to proceed with the medication
When I counsel my patients, I tell them that the study sponsors have to escalate the dose monthly in clinical trials but that doesnt mean I have to practice medicine that way, Orandi explained to MNT
That means Lilly must complete an ongoing clinical trial ACHIEVE-4 which is comparing Foundayo to insulin glargine in patients with type 2 diabetes and overweight or obese who are at elevated cardiovascular risk
Helvaci N, Yildiz BO (2022) Current and emerging drug treatment strategies for polycystic ovary syndrome
Grall-Bronnec, M